Which Diabetes Inventory is a Higher Purchase? By StockNews


© Reuters. Senseonics vs. Novo Nordisk: Which Diabetes Stock is a Better Buy?

Technology integration and inhibitors of DNA synthesis enable pharmaceutical companies to develop drugs for terminal diseases such as diabetes. With the growing number of diabetics in sedentary lifestyles encouraged by coronavirus bans and remote working regulations, companies with approved diabetes drugs are expected to benefit from the high demand for their products. We believe Senseonics (SENS) and Novo (NVO) are examples of companies that should benefit significantly as the demand for diabetes treatment drugs and monitoring devices increases. But which of these two stocks is a better buy now? Let’s find out. Senseonics Holdings, Inc. (NYSE 🙂 and Novo Nordisk A / S (NYSE 🙂 are two established players in the medical industry. SENS is a medical technology company focused on the design, development and marketing of glucose monitoring systems. NVO develops and manufactures pharmaceutical products. NVO is based in Denmark and operates in two segments: Diabetes and Obesity and Biopharm.

Diabetes is increasing at an alarming rate in the West, accelerated by the distant lifestyle and home routines. As a result, pharmaceutical companies have experimented with innovative drugs to cure and treat the disease. Many companies have reported promising results from their clinical studies, suggesting that a drug used to treat diabetes may soon be available in the market.

The size of the global diabetes drug market is projected to reach $ 78.30 billion by 2026, growing at an annual growth rate of 6.1%.

Read on on StockNews

Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. As a result, prices may not be accurate and may differ from the actual market price. This means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this information.

Fusion Media, or persons involved with Fusion Media, assume no liability for any loss or damage caused by reliance on the information contained on this website, such as data, offers, charts and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets. This is one of the riskiest forms of investment possible.